Pyronnet Stéphane, Bousquet Corinne, Najib Souad, Azar Rania, Laklai Hanane, Susini Christiane
INSERM U858, Institut de Médecine Moléculaire de Rangueil, Dpt Cancer/E16, CHU Rangueil, Toulouse Cedex 4, France.
Mol Cell Endocrinol. 2008 May 14;286(1-2):230-7. doi: 10.1016/j.mce.2008.02.002. Epub 2008 Feb 13.
Since its discovery three decades ago as an inhibitor of GH release from the pituitary gland, somatostatin has attracted much attention because of its functional role in the regulation of a wide variety of physiological functions in the brain, pituitary, pancreas, gastrointestinal tract, adrenals, thyroid, kidney and immune system. In addition to its negative role in the control of endocrine and exocrine secretions, somatostatin and analogs also exert inhibitory effects on the proliferation and survival of normal and tumor cells. Over the past 15 years, studies have begun to reveal some of the molecular mechanisms underlying the antitumor activity of somatostatin. This review covers the present knowledge in the antitumor effect of somatostatin and analogs and discusses the perspectives of novel clinical strategies based on somatostatin receptor sst2 gene transfer therapy.
自30年前被发现作为垂体生长激素释放的抑制剂以来，生长抑素因其在调节大脑、垂体、胰腺、胃肠道、肾上腺、甲状腺、肾脏和免疫系统等多种生理功能中的作用而备受关注。除了在控制内分泌和外分泌分泌方面的负面作用外，生长抑素及其类似物对正常细胞和肿瘤细胞的增殖及存活也具有抑制作用。在过去15年中，研究已开始揭示生长抑素抗肿瘤活性的一些分子机制。本综述涵盖了生长抑素及其类似物抗肿瘤作用的现有知识，并讨论了基于生长抑素受体sst2基因转移疗法的新型临床策略的前景。
